Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis

European Psychiatry : the Journal of the Association of European Psychiatrists
M FridmanM Haim Erder

Abstract

There are few approved therapies for adults with attention-deficit/hyperactivity disorder (ADHD) in Europe. Lisdexamfetamine (LDX) is an effective treatment for ADHD; however, no clinical trials examining the efficacy of LDX specifically in European adults have been conducted. Therefore, to estimate the efficacy of LDX in European adults we performed a meta-regression of existing clinical data. A systematic review identified US- and Europe-based randomized efficacy trials of LDX, atomoxetine (ATX), or osmotic-release oral system methylphenidate (OROS-MPH) in children/adolescents and adults. A meta-regression model was then fitted to the published/calculated effect sizes (Cohen's d) using medication, geographical location, and age group as predictors. The LDX effect size in European adults was extrapolated from the fitted model. Sensitivity analyses performed included using adult-only studies and adding studies with placebo designs other than a standard pill-placebo design. Twenty-two of 2832 identified articles met inclusion criteria. The model-estimated effect size of LDX for European adults was 1.070 (95% confidence interval: 0.738, 1.401), larger than the 0.8 threshold for large effect sizes. The overall model fit was adequa...Continue Reading

References

Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Jan 28, 2003·Biological Psychiatry·David MichelsonDenái Milton
Jan 4, 2006·Archives of Pediatrics & Adolescent Medicine·Timothy E WilensJoseph M Lynch
Jun 14, 2006·Journal of Child and Adolescent Psychopharmacology·James J McGoughMark Stein
Jun 2, 2007·The American Journal of Psychiatry·Guilherme PolanczykLuis Augusto Rohde
Feb 19, 2008·The American Journal of Psychiatry·Jeffrey H NewcornUNKNOWN Atomoxetine/Methylphenidate Comparative Study Group
Jan 15, 2009·Journal of Clinical Psychopharmacology·Lenard A AdlerDouglas Kelsey
Sep 19, 2009·European Child & Adolescent Psychiatry·Stephen V Faraone, Jan Buitelaar
Dec 16, 2010·Journal of the American Academy of Child and Adolescent Psychiatry·Timothy E WilensMario D Saltarelli
Mar 23, 2011·Journal of the American Academy of Child and Adolescent Psychiatry·Robert L FindlingLiza Squires
Nov 24, 2011·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Miguel CasasBarbara Schäuble
Dec 17, 2011·Pharmacopsychiatry·E SobanskiP Strohbeck-Kuehner
Feb 9, 2012·The Journal of Clinical Psychiatry·Suzanne M SutherlandDouglas E Feltner
May 16, 2012·Health and Quality of Life Outcomes·Meryl BrodPaul Hodgkins
Jan 22, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·David CoghillLiza Squires
Jul 3, 2013·Pharmacoepidemiology and Drug Safety·Ruth CunillDolors Capellà
Jan 28, 2014·International Journal of Epidemiology·Guilherme V PolanczykLuis A Rohde

❮ Previous
Next ❯

Citations

Dec 24, 2015·Expert Review of Neurotherapeutics·Massimiliano BuoliWiepke Cahn
Apr 7, 2016·CNS Drugs·James E Frampton
Dec 21, 2016·Evidence-based Mental Health·Franco De CrescenzoLuigi Janiri
Sep 1, 2017·Journal of Central Nervous System Disease·Jadwiga NajibAnu Thadavila
Aug 28, 2020·Current Medical Research and Opinion·Jadwiga NajibMaliha Tabassum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.